These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26843569)

  • 1. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transformed migraine--chronic daily headache].
    Bøe MG; Monstad P
    Tidsskr Nor Laegeforen; 1999 Nov; 119(29):4311-3. PubMed ID: 10667127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series.
    Lambru G; Shanahan P; Matharu M
    Cephalalgia; 2015 Oct; 35(12):1115-24. PubMed ID: 25667300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
    Chou DE; Tso AR; Goadsby PJ
    Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.
    Robbins NM; Ito H; Scheinman MM; Goadsby PJ
    Neurology; 2016 Dec; 87(24):2522-2526. PubMed ID: 27837002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Woldeamanuel YW; O'Hare M; DeSouza DD; Cowan RP
    Neurology; 2016 Oct; 87(16):e196-e198. PubMed ID: 27754915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroergotamine and its use in migraine with posterior fossa symptoms.
    Whyte CA; Stillman MJ; Tepper SJ
    Headache; 2010 Oct; 50(9):1419-23. PubMed ID: 20533960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment: Outcomes of migraine therapy with IV dihydroergotamine.
    Charles A
    Neurology; 2016 Mar; 86(9):859. PubMed ID: 26843565
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations of the "carry-over effect" following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study.
    Charles JA; Jotkowitz S
    J Headache Pain; 2005 Feb; 6(1):51-4. PubMed ID: 16362192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP").
    Connelly M; Sekhon S; Stephens D; Boorigie M; Bickel J
    Headache; 2020 Jan; 60(1):101-109. PubMed ID: 31626335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
    Swidan SZ; Lake AE; Saper JR
    Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes.
    Bérard A; Kori S
    Headache; 2012; 52(7):1085-93. PubMed ID: 22612391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early and transient side effects of repetitive intravenous dihydroergotamine.
    Queiroz LP; Weeks RE; Rapoport AM; Sheftell FD; Baskin SM; Siegel SE
    Headache; 1996 May; 36(5):291-4. PubMed ID: 8682669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.